Navigation Links
Immunoglobulin Can Predict Some Diabetic Complications
Date:8/7/2009

Increased excretion of IgM foretells serious cardiovascular issues: study

FRIDAY, Aug. 7 (HealthDay News) -- Swedish researchers say that immunoglobulin M (IgM) is a reliable predictor of cardiovascular complications in people with type 1 diabetes who have diabetic nephropathy (DN) -- kidney damage caused by diabetes.

The study included 139 patients who were followed from 1984 to 2007. Those with increased levels of IgM in their urine at the start of the study were about three times more likely to suffer cardiovascular-related death or to progress to end-stage kidney disease.

The study appears in the journal BMC Medicine.

"To our knowledge, this is the first study to investigate the impact of increased urine IgM excretion on DN disease progression in type 1 diabetes patients," lead researcher Dr. Omran Bakoush of Lund University said in a news release. "We found that those with increased urinary IgM excretion had a higher mortality from cardiovascular causes and higher disease progression rate to end-stage renal disease. This association is largely independent of the level of albuminuria."

Bakoush said the "findings may offer a new approach to manage this rapidly increasing patient population. While measurement of albuminuria is routinely used to evaluate and manage patients with diabetes, increased urine IgM excretion would identify more specifically patients at risk for serious cardiovascular complications (death and renal failure). If increased urine IgM excretion does reflect advanced atherosclerotic vascular disease, clinical trials would be justified to test whether modifying atherosclerotic factors also decrease mortality and incidence of renal failure in diabetic patients with or without IgM-uria."

More information

The MedlinePlus Medical Encyclopedia has more about diabetic nephropathy.



-- Robert Preidt



SOURCE: BioMed Central, news release, Aug. 3, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Sex Hormone Protein May Predict Type 2 Diabetes
2. Brain Scan May Help Predict Cancer Drug Response
3. Biomarker Could Predict Severe Osteoarthritis
4. Obama White House Can Save $3.7 Trillion and Extend Lifespan 29+ Years, Predicts Revolutionary A4M Healthcare Plan
5. Protein level may serve as predictor of severe osteoarthritis
6. Mathematical modeling predicts response to Herceptin
7. Heart Surgeon Shortage Predicted
8. Is somatic hypersensitivity a predictor of irritable bowel syndrome?
9. Biomarkers May Predict Alzheimers
10. Test May Predict Moms Who Will Deliver Prematurely
11. Reed Group Will Debut New Predictive Modeling Tool at DMEC Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Immunoglobulin Can Predict Some Diabetic Complications
(Date:3/23/2017)... ... March 23, 2017 , ... The ... from the NCQA. The accreditation covers StayWell’s asthma, coronary artery disease, congestive heart ... granted to organizations that have excellent programs for the delivery and improvement of ...
(Date:3/23/2017)... ... March 23, 2017 , ... March 23, 2017 - ... to easily reprint customer invoices, bills, statements and other correspondence when they have ... needed to retrieve and print the documents and batch them for efficient handling. ...
(Date:3/23/2017)... OR (PRWEB) , ... March 23, 2017 , ... Sharon ... Water, Global Climate Change and Your Health on VoiceAmerica, recently talked on her program ... she also used the occasion to remind listeners of an important distinction. World Water ...
(Date:3/23/2017)... ... March 23, 2017 , ... Corra Group is ... competitive pricing. Verisys through its FACIS and other services maintains the ... actions. , “We are delighted to be able to offer these various products ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... New MEDDEV 2.7/1 Rev. 4 Guidance, **An FDAnews Webinar**, April 4, 2017 ... will the new EU MDR language change the way manufacturers approach CERs? ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... 23, 2017  Cornerstone Pharmaceuticals, Inc., a ... milestone today.  Following successful End-of-Phase I (EOP1) ... and Drug Administration (FDA), the Company has ... path forward to conduct pivotal trials of ... acute myeloid leukemia (AML) and pancreatic cancer. ...
(Date:3/23/2017)... March 23, 2017 Piramal ... Limited, anuncia el nombramiento de Stuart E. ... plataforma de servicios integrados completa para su base ... cargo clave en el crecimiento y ejecución de ... responsable de impulsar todas las actividades de desarrollo ...
(Date:3/23/2017)... Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) ... a Phase 1 study of MM-310 in solid tumors. ... novel taxane and targets the EphA2 receptor, a protein ... major tumor types, including prostate, ovarian, bladder, gastric, pancreatic ... study is an important step in evaluating MM-310,s safety ...
Breaking Medicine Technology: